Effects of Dimethyltryptamine in Healthy Subjects

This double-blind, placebo-controlled crossover trial (n=31) aims to investigate the effects of N,N-dimethyltryptamine (DMT) in healthy subjects. DMT is a naturally-occurring psychedelic substance commonly used in recreational and spiritual contexts. The study focuses on intravenous administration of DMT to induce an altered state of consciousness.

Four different intravenous DMT administration schedules, including varying doses and bolus/maintenance perfusion conditions, are tested. The study aims to examine the subjective and autonomic effects of DMT in healthy subjects. The primary outcome measures include the altered states of consciousness profile and subjective effect ratings over time. Secondary outcome measures include subjective mood ratings, mystical-type experiences, autonomic effects, plasma levels of DMT, plasma levels of blood-derived neurotrophic factor (BDNF), plasma levels of oxytocin, renal clearance of DMT, effect moderation through personality traits, and adverse effects. The study started on June 18, 2021, and was completed on September 22, 2022. It was conducted at the University Hospital in Basel, Switzerland.

Topic Healthy Subjects
Compound DMT Placebo
Country Switzerland
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.

Papers

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
This double-blind, placebo-controlled crossover trial (n=27) investigated different intravenous DMT administration regimens, including placebo, low and high infusion (0.6-1mg/min), and bolus doses (15-25mg) combined with low and high infusion. The study found that bolus doses rapidly induced intense psychedelic effects, with infusions causing slowly increasing, dose-dependent effects.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.